Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
32 hedge funds and large institutions have $27.5M invested in Biolase, Inc. in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
7% more funds holding
Funds holding: 30 → 32 (+2)
28% less capital invested
Capital invested by funds: $38.5M → $27.5M (-$10.9M)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$74.2K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$59.4K |
| 3 |
GF
Gabelli Funds
Rye,
New York
|
+$44.5K |
| 4 |
Goldman Sachs
New York
|
+$29.7K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$29.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$134K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$89.1K |
| 3 |
BlackRock
New York
|
-$74.2K |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$59.4K |
| 5 |
D.E. Shaw & Co
New York
|
-$29.7K |
BIOL Hedge Fund Activity: Q2 2017 in Review
32 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q2 2017, worth a combined $27.5M — down 28% from $38.5M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BIOL positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Trellus Management Company, adding an estimated $74.2K. The largest seller was Consonance Capital Management, cutting an estimated $134K.
- 32 institutional investors held Biolase, Inc. (BIOL) as of Q2 2017, up from 30 in Q1 2017.
- Funds reported $27.5M of Biolase, Inc. stock for Q2 2017, down 28% quarter-over-quarter.
- 3 funds opened new Biolase, Inc. positions in Q2 2017 and 1 closed out, a net change of +2 holders.
- The largest Biolase, Inc. buyer in Q2 2017 was Trellus Management Company, an estimated $74.2K added.
- The largest Biolase, Inc. seller in Q2 2017 was Consonance Capital Management, an estimated $134K sold.
Based on aggregated 13F filings for Q2 2017.